Former Kite Pharma Exec Anthony Polverino Named Zymeworks CSO

Anthony Polverino has been appointed executive vice president of early development and chief scientific officer of Vancouver, BC-based Zymeworks (NYSE: [[ticker:ZYME]]). Polverino most recently worked at Kite Pharma, where he was interim chief scientific officer, and prior to that, vice president of research. Kite was acquired by Gilead Sciences (NASDAQ: [[ticker:GILD]]) last year. Zymeworks develops cancer treatments called bispecific antibodies. The company is currently testing its lead drug, ZW25, in a Phase 1 study as a potential treatment for breast cancer.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.